Siddhartha Kadia

Dr. Kadia has a deep background in executive management and public company governance across a range of global businesses, predominantly in the Life Sciences Tools, Research, Diagnostics and TIC (Testing, Inspection and Certification) industries. Dr. Kadia was formerly President, CEO and Director of EAG Laboratories until its acquisition by Eurofins Scientific in 2017. He continued to serve as the CEO of EAG laboratories until December 2018. Prior to EAG, he served in a number of senior roles including the President of Life Sciences Division at Life Technologies Corporation at the time of its acquisition by ThermoFisher Scientific in February 2014.

Dr. Kadia has extensive Board experience and has previously served as a Director of two US listed companies, Newport Corporation (NSDQ: NEWP), Volcano Corporation (NSDQ: VOLC) and of the privately owned EAG Laboratories.  He currently serves on the Board of Directors of ALS Global, an ASX listed public global TIC company headquartered in Australia.  He previously served as a management consultant at McKinsey and Company.  Dr. Kadia has executive experience working in the US, Europe, Japan and China and has an extensive global network in scientific enterprise.

Dr. Kadia obtained his Ph.D. in biomedical engineering from The Johns Hopkins University, followed by a post-doctoral fellowship in Neuroscience at Johns Hopkins University School of Medicine, Baltimore.  He also holds an M.S. in biomedical engineering from Rutgers University, New Jersey, and a B.E in electronics and telecommunications from Gujarat University in India.